208 related articles for article (PubMed ID: 16971805)
1. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells.
Huang YW; Richardson JA; Vitetta ES
Cancer Res; 1995 Feb; 55(3):610-6. PubMed ID: 7834632
[TBL] [Abstract][Full Text] [Related]
3. The generation and anti-myeloma activity of a chimeric anti-CD54 antibody, cUV3.
Smallshaw JE; Coleman E; Spiridon C; Vitetta ES
J Immunother; 2004; 27(6):419-24. PubMed ID: 15534485
[TBL] [Abstract][Full Text] [Related]
4. Effect of an anti-CD54 (ICAM-1) monoclonal antibody (UV3) on the growth of human uveal melanoma cells transplanted heterotopically and orthotopically in SCID mice.
Wang S; Coleman EJ; Pop LM; Brooks KJ; Vitetta ES; Niederkorn JY
Int J Cancer; 2006 Feb; 118(4):932-41. PubMed ID: 16152588
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies.
Spiridon CI; Guinn S; Vitetta ES
Clin Cancer Res; 2004 May; 10(10):3542-51. PubMed ID: 15161714
[TBL] [Abstract][Full Text] [Related]
6. The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines.
Brooks KJ; Coleman EJ; Vitetta ES
Int J Cancer; 2008 Nov; 123(10):2438-45. PubMed ID: 18752248
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
[TBL] [Abstract][Full Text] [Related]
8. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
Li B; Shi S; Qian W; Zhao L; Zhang D; Hou S; Zheng L; Dai J; Zhao J; Wang H; Guo Y
Cancer Res; 2008 Apr; 68(7):2400-8. PubMed ID: 18381448
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
10. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
11. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
12. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
14. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
15. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
Liu Y; Zheng M; Lai Z; Xiong D; Fan D; Xu Y; Peng H; Shao X; Xu Y; Yang M; Wang J; Liu H; Xie Y; Yang C; Zhu Z
Cancer Lett; 2004 Mar; 205(2):143-53. PubMed ID: 15036646
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
18. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
19. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.
Tong AW; Huang YW; Zhang BQ; Netto G; Vitetta ES; Stone MJ
Anticancer Res; 1993; 13(3):593-7. PubMed ID: 8391243
[TBL] [Abstract][Full Text] [Related]
20. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
